PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges
Open Access
- 3 December 2008
- journal article
- review article
- Published by Wiley in Brain Pathology
- Vol. 19 (1) , 112-120
- https://doi.org/10.1111/j.1750-3639.2008.00233.x
Abstract
The PI3 kinase (PI3K) family plays a complex role in cell biology and metabolism. Signaling through the PI3Ks is frequently activated in many human cancers, including glioblastoma, because of gain‐of‐function mutations in PIK3CA or loss of PTEN. Experiments involving genetic mouse models and small molecule inhibitors have helped to elucidate the roles of the regulatory and catalytic subunits of PI3K in metabolism and cancer. Downstream of PI3K is Akt, a critical effector of growth, proliferation and survival. The suggested dependence of glioblastoma tumors on PI3K signaling implies that PI3K inhibitors should lead to effective killing of these cancer cells, but that has been shown not to be the case. The engagement of other survival pathways in response to PI3K inhibition prompts the need to develop combination therapies that promote cytotoxicity in cancer cells.Keywords
This publication has 78 references indexed in Scilit:
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformationProceedings of the National Academy of Sciences, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004